Payment overview · 2025
General Payments
$467.82
23 reported records · 14 companies
Healthcare provider profile · identity verified
Hemen Padhiar, MD
Allopathic & Osteopathic Physicians|Family Medicine · CUMMING, GA · NPI 1740265099
Verified facts
What the public records show
CMS Open Payments records show Hemen Padhiar, MD received $467.82 in general payments during 2025 across 23 reported records.
GlaxoSmithKline, LLC. accounted for 13.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $64.47 | 13.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $62.29 | 13.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $47.70 | 10.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $44.15 | 9.4% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $42.51 | 9.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.15 | 7.7% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $29.11 | 6.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $28.35 | 6.1% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $28.31 | 6.0% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $25.45 | 5.4% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$19.87 | 4.2% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.06 | 3.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.59 | 3.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $5.81 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $467.82 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $67.96 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $64.47 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $64.47 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $44.15 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $29.11 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $28.35 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $28.31 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.31 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $20.50 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| INTERSTIM Normalized: interstim |
Device | Medtronic, Inc. | $19.87 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $18.06 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.56 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.56 | 1 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.70 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $13.59 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $5.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 99 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 51 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 46 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
46 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
99 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 525 | 167 |
| Atorvastatin Calcium | Atorvastatin Calcium | 464 | 140 |
| Alprazolam | Alprazolam | 401 | 105 |
| Amlodipine Besylate | Amlodipine Besylate | 338 | 118 |
| Lisinopril | Lisinopril | 301 | 102 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 271 | 95 |
| Omeprazole | Omeprazole | 255 | 81 |
| Escitalopram Oxalate | Escitalopram Oxalate | 249 | 88 |
| Temazepam | Temazepam | 214 | 68 |
| Losartan Potassium | Losartan Potassium | 212 | 76 |
| Lorazepam | Lorazepam | 203 | 56 |
| Metformin Hcl | Metformin Hcl | 202 | 72 |
| Pantoprazole Sodium | Pantoprazole Sodium | 182 | 68 |
| Tramadol Hcl | Tramadol Hcl | 178 | 56 |
| Montelukast Sodium | Montelukast Sodium | 168 | 55 |
| Methylprednisolone | Methylprednisolone | 163 | 133 |
| Gabapentin | Gabapentin | 161 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 148 | 49 |
| Carvedilol | Carvedilol | 137 | 41 |
| Sertraline Hcl | Sertraline Hcl | 131 | 49 |
| Simvastatin | Simvastatin | 131 | 43 |
| Trazodone Hcl | Trazodone Hcl | 121 | 46 |
| Clonazepam | Clonazepam | 117 | 36 |
| Azithromycin | Azithromycin | 111 | 97 |
| Eliquis | Apixaban | 105 | 28 |
| Mounjaro | Tirzepatide | 99 | 25 |
| Bupropion Xl | Bupropion Hcl | 96 | 37 |
| Allopurinol | Allopurinol | 95 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 95 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 34 |
| Furosemide | Furosemide | 92 | 30 |
| Meloxicam | Meloxicam | 91 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 84 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 83 | 41 |
| Famotidine | Famotidine | 80 | 24 |
| Buspirone Hcl | Buspirone Hcl | 77 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 75 | 33 |
| Oxybutynin Chloride | Oxybutynin Chloride | 74 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 72 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 67 | 17 |
| Cephalexin | Cephalexin | 66 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 61 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 20 |
| Pregabalin | Pregabalin | 57 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 16 |
| Prednisone | Prednisone | 54 | 39 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 20 |
| Ozempic | Semaglutide | 51 | 14 |
| Ezetimibe | Ezetimibe | 50 | 21 |
| Cefdinir | Cefdinir | 48 | 42 |
| Dutasteride | Dutasteride | 47 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 46 | 28 |
| Synthroid | Levothyroxine Sodium | 46 | 17 |
| Glipizide | Glipizide | 45 | 15 |
| Memantine Hcl | Memantine Hcl | 45 | 14 |
| Myrbetriq | Mirabegron | 44 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 28 |
| Finasteride | Finasteride | 41 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 41 | 15 |
| Xarelto | Rivaroxaban | 37 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | 11 |
| Potassium Chloride | Potassium Chloride | 36 | 16 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 35 | 31 |
| Glimepiride | Glimepiride | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 29 |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 23 |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Risperidone | Risperidone | 30 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 25 | 11 |
| Sotalol | Sotalol Hcl | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Fluconazole | Fluconazole | 23 | 17 |
| Mirtazapine | Mirtazapine | 23 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 15 |
| Dilt-Xr | Diltiazem Hcl | 22 | suppressed |
| Eszopiclone | Eszopiclone | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 13 |
| Cholestyramine | Cholestyramine (With Sugar) | 21 | 16 |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | 11 |
| Lovastatin | Lovastatin | 19 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Nystatin | Nystatin | 15 | 11 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Diovan Hct | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $467.82 · 23 records | GlaxoSmithKline, LLC. | AREXVY, Cologuard Collection Kit, INSPIRE, INTERSTIM, JARDIANCE, KISUNLA, LEQEMBI, MOUNJARO, NEXLETOL, Ozempic, QULIPTA, REXULTI, Repatha, Rybelsus, SHINGRIX, SYNTHROID, TZIELD, UBRELVY, VOQUEZNA, VRAYLAR | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error